Calreticulin (CALR)-mutated myeloproliferative neoplasms research hub

A study of JNJ-88549968 for the treatment of calreticulin (CALR)-mutated myeloproliferative neoplasms

This early-stage clinical trial tests a new medicine, JNJ-88549968, for adults with rare blood cancers called MPNs who have a CALR gene change. Based at Guy's Hospital in London, the study aims to find the safest dose and learn how effectively it helps the immune system fight cancer.